Latest Breaking News On - Head of preclinical development - Page 2 : vimarsana.com

Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round

ILC's Alfacyte product has potential to become a game-changing antiviral treatment in the ongoing global fight against Covid-19 Scottish biotech ICL Therapeutics has set its sights on a Series A round

Glasgow cityUnited kingdomAlan walkerRobert kopplePeter bainsHead of preclinical developmentDepartment of immunologyUniversity of strathclydeBusiness wireVice presidentGlobal commercial operationsScottish enterpriseLos angeles basedClinical trial authorisationPreclinical developmentChief scientific officer

Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program

Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalInstitut pasteurChristine petitNecker enfants maladesNatalie loundonBarbara kelleyNawal ouzrenDavid lawrenceDrug administrationEuropean medicines agencyInternational media relationsCompany rd dayHead of preclinical developmentHearing loss association of americaConsiliumstrategic communications

Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease

Thursday April 6, 2023, at 8am EDT, 2pm CEST Regulatory News: Sensorion, (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies

United statesFrance generalDennis riedlChristine petitInstitut pasteurBarbara kelleyNecker enfants maladesNawal ouzrenDavid lawrenceNatalie loundonMatthew cole jessica hodgsonHead of preclinical developmentHearing institute institutCommunications europe franceHearing loss association of americaInternational media relations

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Dario lehouxJules abrahamMichael messingerExchange commissionHead of preclinical developmentContrafect corporation nasdaqEuropean congressContrafect corporationCompany breakthrough therapyClinical microbiologyInfectious diseasesAnnual meetingBreakthrough therapyAntibacterial agentsNew compoundsPreclinical data

LAKEWOOD-AMEDEX APPOINTS CHIEF MEDICAL OFFICER AND ADDS NEW MANAGEMENT TEAM MEMBERS

/PRNewswire/ Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of.

United statesHarvard universityDonald kleinSteve parkinsonPeterb corrKanneganti murthyKelvin cooperSumita paulLisa sherHead of preclinical developmentDrug administrationAmedex incHarvard medical schoolGlobal head of clinical developmentProgram lead for pemziviptadilMaster of public health